Duality of lipid mediators in host response against Mycobacterium tuberculosis: Good cop, bad cop

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Dietzold, Jillian ^a   Gopalakrishnan, Archana ^a   Salgame, Padmini ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ICOSANOID; LIPID; LIPOXIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIRULENCE; CELL DEATH; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84924598127     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-29     Document Type: Article

References (63)

1. Global tuberculosis report 2013. World Health Organization (WHO); 2013. [http://www.who.int/tb/publications/global-report/en/].
2. Zhang Y, Yew WW, Barer MR: Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012, 56:2223-30.
3. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ: The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013, 43:1995-2002.
4. Gopalan N, Andrade BB, Swaminathan S: Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction. Expert Rev Clin Immunol 2014, 10:631-45.
5. Vilaplana C, marzo E, Tapia G, Diaz J, Garcia V, Cardona PH: Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
6. Critchley JA, Young F, Orton L, Garner P: Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13:223-37.
7. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN: Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity 2013, 39:885-98.
8. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:69-74.
9. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-87.
10. Serhan CN, Hong S, Gronert K, colgan SP, Devchand PR, Mirick G, Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-37.
11. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-9.
12. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-61.
13. Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C: The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-87.
14. O'Garra A, Redford PS, McNab FW, Bloom CI,Wilkinson RJ, Berry MP: The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
15. Divangahi M, Behar SM, Remold H: Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis. Adv Exp Med Biol 2013, 783:103-20.
16. Berry MP, Blankley S, Graham CM, Bloom CI, O'Garra A: Systems approaches to studying the immune response in tuberculosis. Curr Opin Immunol 2013, 25:579-87.
17. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, Aliberti J: Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005, 115:1601-6.
18. Peres CM, de Paula L, Medeiros AI, Sorgi CA, Soares EG, Carlos D, Peters-Golden M, Silva CL, Faccioli LH: Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 2007, 9:483-9.
19. Peres-Buzalaf C, de Paula L, Frantz FG, Soares EM, Medeiros AI, Peters-Golden M, Silva CL, Faccioli LH: Control of experimental pulmonary tuberculosis dependsmore on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins. Prostaglandins Leukot Essent Fatty Acids 2011, 85:75-81.
20. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Werz O, Rüsch-Gerdes S, Horstmann RD, Meyer CG: ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum Mol Genet 2008, 17:1052-60.
21. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, bang ND, Hagge DA, Khadge S, King MC, Hawn TR, Moens CB, Ramakrishnan L: The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-30.
22. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King MC, Serhan CN, Ramakrishnan L: Host genotypespecific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-46.
23. Tobin DM, Roca FJ, Ray JP, Ko DC, Ramakrishnan L: An enzyme that inactivates the inflammatory mediator leukotriene b4 restricts mycobacterial infection. PLoS One 2013, 8:e67828.
24. Török ME, Nguyen DB, Tran TH, Nguyen TB, Thwaites GE, Hoang TQ, Nguyen HD, Tran TH, Nguyen TC, Hoang HT, Wolbers M, Farrar JJ: Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 2011, 6:e27821.
25. Spira A, Carroll JD, Liu G, Aziz Z, Shah V, Kornfeld H, Keane J: Apoptosis genes in human alveolar macrophages infected with virulent or attenuated Mycobacterium tuberculosis: a pivotal role for tumor necrosis factor. Am J Respir Cell Mol Biol 2003, 29:545-51.
26. Park JS, Tamayo MH, Gonzalez-Juarrero M, Orme IM, Ordway DJ: Virulent clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular necrosis but minimal apoptosis in murine macrophages. J Leukoc Biol 2006, 79:80-6.
27. Chen M, Gan H, Remold HG: A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol 2006, 176:3707-16.
28. Gan H, Lee J, Ren F, Chen M, Kornfeld H, Remold HG: Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol 2008, 9:1189-97.
29. Molloy A, Laochumroonvorapong P, Kaplan G: Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med 1994, 180:1499-509.
30. Fratazzi C, Arbeit RD, Carini C, Remold HG: Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 1997, 158:4320-7.
31. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH: Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003, 9:1039-46.
32. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SH, Schaible UE: Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24:105-17.
33. Duan L, Gan H, Golan DE, Remold HG: Critical role of mitochondrial damage in determining outcome of macrophage infection with Mycobacterium tuberculosis. J Immunol 2002, 169:5181-7.
34. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, Serhan CN, Behar SM, Remold HG: Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008, 205:2791-801.
35. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, Fortune S, Behar SM, Remold HG: Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009, 10:899-906.
36. Kaul V, Bhattacharya D, Singh Y, Van Kaer L, Peters-Golden M, Bishai WR, Das G: An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice. J Infect Dis 2012, 206:1816-25.
37. Rojas M, Barrera LF, Puzo G, Garcia LF: Differential induction of apoptosis by virulent Mycobacteriumtuberculosis in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. J Immunol 1997, 159:1352-61.
38. Davis JM, Ramakrishnan L: The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009, 136:37-49.
39. Aguiló N, Uranga S, Marinova D, Martín C, Pardo J: Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis. Cell Death Dis 2014, 5:e1343.
40. Aporta A, Arbues A, Aguilo JI, Monzon M, Badiola JJ, de Martino A, Ferrer N, Marinova D, Anel A, Martin C, Pardo J: Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death. PLoS One 2012, 7:e45213.
41. Aguiló N, Marinova D, Martín C, Pardo J: ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question. Front Cell Infect Microbiol 2013, 3:88.
42. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, Barry C, Kaplan G: Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005, 25:694-701.
43. Manca C1, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE 3rd, Freedman VH, Kaplan G: Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci USA 2001, 98:5752-7.
44. Antonelli LR, Gigliotti Rothfuchs A, Gonçalves R, Roffê E, Cheever AW, Bafica A, Salazar AM, Feng CG, Sher A: Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/ macrophage population. J Clin Invest 2010, 120:1674-82.
45. Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A, O' Garra A: Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis 2014, 209:270-4.
46. Stanley SA, Johndrow JE, Manzanillo P, Cox JS: The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007, 178:3143-52.
47. Dorhoi A, Yeremeev V, Nouailles G,Weiner J 3rd, Jörg S, Heinemann E, Oberbeck-Müller D, Knaul JK, Vogelzang A, Reece ST, Hahnke K, Mollenkopf HJ, Brinkmann V, Kaufmann SH: Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol 2014, 44:2380-93.
48. McNab FW, Ewbank J, Rajsbaum R, Stavropoulos E, Martirosyan A, Redford PS, Wu X, Graham CM, Saraiva M, Tsichlis P, Chaussabel D, Ley SC, O'Garra A: TPL-2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J Immunol 2013, 191:1732-43.
49. Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, Myers TG, Rabin RL, Trinchieri G, Sher A, Feng CG: Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J Immunol 2011, 187:2540-7.
50. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, Oland S, Gordon S, Sher A: Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35:1023-34.
51. Mayer-Barber KD1, Barber DL, Shenderov K, White SD, Wilson MS, Cheever A, Kugler D, Hieny S, Caspar P, Núñez G, Schlueter D, Flavell RA, Sutterwala FS, Sher A: Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010, 184:3326-30.
52. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, Speelman P, van Deventer SJ, van Der Poll T: Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis 2000, 182:902-8.
53. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, Jacobs M, RyffelB,Quesniaux VF: IL-1 receptor-mediated signal is anessential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007, 179:1178-89.
54. Sugawara I, Yamada H, Hua S, Mizuno S: Role of interleukin (IL)-1 type 1 receptor in mycobacterial infection. Microbiol Immunol 2001, 45:743-50.
55. McNab FW, Ewbank J, Howes A, Moreira-Teixeira L, Martirosyan A, Ghilardi N, Saraiva M, O'Garra A: Type I IFN Induces IL-10 Production in an IL-27-Independent Manner and Blocks Responsiveness to IFN-gamma for Production of IL-12 and Bacterial Killing in Mycobacterium tuberculosis-Infected Macrophages. J Immunol 2014, 193:3600-12.
56. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O'Garra A: An interferoninducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-7.
57. Maertzdorf J, Ota M, Repsilber D, Mollenkopf HJ, Weiner J, Hill PC, Kaufmann SH: Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One 2011, 6: e26938.
58. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, Khor CC, Alisjahbana B, van Crevel R, Marzuki S, Seielstad M, van de Vosse E, Hibberd ML: Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One 2012, 7:e45839.
59. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, Yuan X, Zhang G, Cai Y, Babu S, Catalfamo M, Salazar AM, Via LE, Barry CE 3rd, Sher A: Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
60. Tam VC, Quehenberger O, Oshansky CM, Suen R, Armando AM, Treuting PM, Thomas PG, Dennis EA, Aderem A: Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 2013, 154:213-27.
61. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN: Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002, 8:1018-23.
62. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP: Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002, 99:3902-7.
63. Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A, Gillard J, Wong G, Kobinger G, Xing Z, Couture C, Joubert P, Fritz JH, Powell WS, Divangahi M: Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014, 40:554-68.